Topical corticosteroids

Pipeline

Status by Indication[2][1]

Competition

Competitive Landscape

8 competitors in Dermatitis, Atopic

#DrugCompanyPhaseTrials

1

Amlitelimab

Sanofi

Phase 3

72

Topical Calcineurin Inhibitors

Sanofi

Phase 3

23

Topical corticosteroids

Sanofi

Phase 3

34

JNJ-95597528

Johnson & Johnson

Phase 2

15

Calcineurin Inhibitors

Sanofi

Preclinical

26

Oral Corticosteroids

Sanofi

Preclinical

1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Dermatitis, Atopic3 trials

A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Participants of Previous Amlitelimab Clinical Trials in Moderate to Severe Atopic Dermatitis.

Active, not recruiting·Sanofi·Preclinical·NCT05492578·1,856 enrolled

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (AD) Who Are on Background Topical Corticosteroids and Have Had an Inadequate Response to Prior Biologic Therapy or Oral Janus Kinase (JAK) Inhibitor Treatment

Active, not recruiting·Sanofi·Phase 3·NCT06241118·464 enrolled

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids

Completed·Sanofi·Phase 3·NCT06224348·643 enrolled

Details

Drug Info

Related News